[{"orgOrder":0,"company":"TerSera Canada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Goserelin Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Oncology","graph2":"Approved FDF","graph3":"TerSera Canada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Implant","sponsorNew":"TerSera Canada \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"TerSera Canada \/ Undisclosed"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cetirizine Dihydrochloride","moa":"Histamine H1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"TerSera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TerSera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"Margetuximab","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Approved FDF","graph3":"TerSera Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"TerSera Therapeutics \/ TerSera Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"TerSera Therapeutics \/ TerSera Therapeutics"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"TerSera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Telotristat","moa":"Tryptophan 5-hydroxylase","graph1":"Oncology","graph2":"Phase II","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TerSera Therapeutics \/ TerSera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"TerSera Therapeutics \/ TerSera Therapeutics"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Telotristat Ethyl","moa":"Tryptophan 5-hydroxylase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"TerSera Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TerSera Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"TerSera Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TerSera Therapeutics","sponsor":"Lexicon pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Telotristat Ethyl","moa":"Tryptophan 5-hydroxylase","graph1":"Oncology","graph2":"Phase II","graph3":"TerSera Therapeutics","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.22,"dosageForm":"Undisclosed","sponsorNew":"TerSera Therapeutics \/ TerSera Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"TerSera Therapeutics \/ TerSera Therapeutics"}]

Find Clinical Drug Pipeline Developments & Deals by TerSera Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Under the agreement, TerSera will acquire global rights to Margenza (margetuximab) from MacroGenics. It is indicated for the treatment of HER2-positive breast cancer.

                          Product Name : Margenza

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Undisclosed

                          October 22, 2024

                          Lead Product(s) : Margetuximab

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : MacroGenics

                          Deal Size : $75.0 million

                          Deal Type : Acquisition

                          blank

                          02

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Health Canada has approved a sNDA for ZOLADEX LA (goserelin acetate), GnRH agonist at 10.8mg every 12 weeks for the management of ER+ early breast cancer in pre- and perimenopausal women.

                          Product Name : Zoladex

                          Product Type : Peptide, Unconjugated

                          Upfront Cash : Inapplicable

                          May 07, 2024

                          Lead Product(s) : Goserelin Acetate

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.

                          Product Name : Xermelo

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          November 09, 2021

                          Lead Product(s) : Telotristat Ethyl

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : First randomized, double-blind, controlled trial evaluating IV cetirizine versus IV diphenhydramine in the prevention of hypersensitivity infusion reactions. QUZYTTIR is the first and only injectable second-generation H1 antihistamine to be approved by t...

                          Product Name : Quzyttir

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 05, 2021

                          Lead Product(s) : Cetirizine Dihydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : Telotristat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Neuroendocrine Tumors.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 10, 2020

                          Lead Product(s) : Telotristat

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Lowell Anthony, MD

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          The MedTech Conference
                          Not Confirmed
                          The MedTech Conference
                          Not Confirmed

                          Details : As part of the transaction, TerSera has agreed to assume the currently ongoing TELE-ABC Phase 2 clinical study of XERMELO in biliary tract cancer patients.

                          Product Name : Xermelo

                          Product Type : Miscellaneous

                          Upfront Cash : $159.0 million

                          July 30, 2020

                          Lead Product(s) : Telotristat Ethyl

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Lexicon pharmaceuticals

                          Deal Size : $224.0 million

                          Deal Type : Agreement

                          blank